Dr. Nathanael G. Bailey is a member of the Division of Hematopathology.
Clinical Expertise
Dr. Bailey is active on the hematopathology service interpreting lymph node and bone marrow biopsies, reviewing blood films and body fluid specimens, interpreting flow cytometric studies, and providing consultative services on outside lymph node and bone marrow biopsy specimens. He additionally has experience interpreting genetic/genomic assays, and he is involved in bringing on new genetic tests for hematolymphoid neoplasms at the University of Pittsburgh.
Certifications
Specialty Certification
07/2009-12/2019 American Board of Pathology - Anatomic and Clinical Pathology #09-076
09/2010-12/2020 American Board of Pathology - Hematopathology #S-10-278
09/2011-12/2021 American Board of Pathology and American Board of Medical Genetics - Molecular Genetic Pathology #S-11-090
Medical Licensure
09/2006-06/2014 State of WV, Medical License
03/2010-01/2017 State of MI, Controlled Substance
03/2010-01/2017 State of MI, Medical License
04/2016-Present State of PA, Medical License
Dr. Bailey's research interests include the molecular pathogenesis of hematolymphoid neoplasms and the translation of these findings into routine patient care. He participated in studies that examined the genomic landscape of splenic marginal zone lymphoma, T-cell prolymphocytic leukemia, and Sézary syndrome. Dr. Bailey has led translational studies regarding the efficacy of immunohistochemical detection of mutant BRAF protein in hairy cell leukemia, and is involved in projects evaluating subclassification of peripheral T-cell lymphoma according to its "cell of origin". In addition, Dr. Bailey has written several book chapters and review articles.
- Anekpuritanang T, Klairmont MM, Gradowski J, Hagiwara K, Bailey NG, Chandra P, Liu Y, Mulder H, Easton J, Zhang J, Martin MG, Owczarczyk AB, Dunlap J, Fan G, Press RD, Raess PW. In a multi-institutional cohort of myeloid sarcomas, NFE2 mutation prevalence is lower than previously reported. Blood Advances 2021 Sep 24;bloodadvances.2021004983. doi: 10.1182/bloodadvances.2021004983.
- Zilla ML, Khoshnoodi P, Bailey NG, Herradura A, Lee SJ, John I. Epithelioid inflammatory myofibroblastic sarcomas are not exclusive to ventral cavity sites. Histopathology. 2022 Feb;80(3):610-612. doi: 10.1111/his.14582. Epub 2021 Dec 13. PMID: 34610169.
- Martinez RJ, Kang Q, Nennig D, Bailey NG, Brown NA, Betz BL, Tewari M, Thyagarajan B, Bachanova V, Mroz P. One-Step Multiplexed Droplet Digital Polymerase Chain Reaction for Quantification of p190 BCR-ABL1 Fusion Transcript in B-Lymphoblastic Leukemia. Arch Pathol Lab Med. 2022 Jan 1;146(1):92-100. doi: 10.5858/arpa.2020-0454-OA. PMID: 33769465.
- Bailey NG. Visualization of the Effect of Assay Size on the Error Profile of Tumor Mutational Burden Measurement. Genes 2022, 13(3):432; doi: 10.3390/genes13030432
- Maurer, LM, Daley JD, Mukherjee E, Venier RE, Julian CM, Bailey NG, Jacobs MF, Kumar-Sinha C, Raphael H, Periyapatna N, Weiss K, Janeway KA, Mody R, Lucas PC, McAllister-Lucas L, Bailey KM. BARD1 loss and GBP1 expression enhance sensitivity to DNA damage in Ewing sarcoma. Cancer Res Commun 2022 2(4):220-232
- Hegazy SE, Bailey NG. Progression of CCND1– in situ mantle cell neoplasia to CCND1–mantle cell lymphoma. Blood. 2022 140(10):1182
- Baloda V, Wheeler SE, Murray DL, Kohlhagen MC, Vos JA, Yatsenko SA, Agha ME, Djokic M, Swerdlow SH, Bailey NG. Mu heavy chain disease with MYD88 L265P mutation: An unusual manifestation of lymphoplasmacytic lymphoma. Diagn Pathol. 2022 17(1):63.
- Gao X, Wang C, Abdelrahman S, Kady N, Murga-Zamalloa C, Gann P, Sverdlov M, Wolfe A, Polk A, Brown N, Bailey NG, Inamdar K, Casavilca-Zambrano S, Montes J, Barrionuevo C, Taxa L, Reneau J, Siebel CW, Maillard I, Wilcox RA. Notch signaling promotes mature T-cell lymphomagenesis. Cancer Res. 2022 Aug 25:CAN-22-1215.
- Cillo AR, Mukherjee E, Bailey NG, Onkar S, Daley J, Salgado C, Li X, Li D, Ranganathan S, Burgess M, Sembrat J, Weiss K, Watters R, Bruno TC, Vignali DAA, Bailey KM. Ewing sarcoma and osteosarcoma have distinct immune signatures and intercellular communication networks. Clin Cancer Res. 2022 Sep 8;CCR-22-1471. doi: 10.1158/1078-0432.CCR-22-1471.
- Geng X, Wang C, Gao X, Chowdhury P, Weiss J, Villegas JA, Saed B, Perera T, Hu Y, Reneau J, Sverdlov M, Wolfe A, Brown N, Harms P, Bailey NG, Inamdar K, Hristov AC, Tejasvi T, Montes J, Barrionuevo C, Taxa L, Casavilca S, de Pádua Covas Lage JLA, Culler HF, Pereira J, Runge JS, Qin T, Tsoi LC, Hong HS, Zhang L, Lyssiotis CA, Ohe R, Toubai T, Zevallos-Morales A, Murga-Zamalloa C, Wilcox RA. GATA-3 is a proto-oncogene in T-cell lymphoproliferative neoplasms. Blood Cancer J. 2022 Nov 4;12(11):149. doi: 10.1038/s41408-022-00745-y. PMID: 36329027; PMCID: PMC9633835.
- Lontos K, Tsagianni A, Agha M, Raptis A, Hou JZ, Farah R, Redner RL, Im A, Dorritie KA, Sehgal A, Rossetti J, Aggarwal N, Saul M, Boyiadzis M, Bailey NG. Prognostic significance of blast immunophenotype on first post-induction bone marrow biopsy. Leuk Lymphoma. 2023 Feb 1:1-3. doi: 10.1080/10428194.2023.2172981. Epub ahead of print. PMID: 36722791.
- Davis AR, Canady BC, Aggarwal N, Bailey NG Clinicopathologic features of IDH2 R172 Mutated Myeloid Neoplasms. Am J Clin Pathol 2023 doi: 10.1093/ajcp/aqad019
- Alsouqi A, Kleinberger J, Werner TS, Awan R, Chopra S, Rea B, Aggarwal N, Yatsenko SA, Farah R, Bailey NG. Novel FIP1L1::KIT fusion in a myeloid neoplasm with eosinophilia, T-lymphoblastic transformation, and dasatinib response. Haematologica 2023 (accepted)
- Chopra S, Bailey NG. Application of the International Consensus Classification and World Health Organization 5th Edition Classification to a Series of Myeloid Neoplasms. Am J Clin Pathol 2023 (accepted, in press).